Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
EZH2 deletion does not affect acinar regeneration but restricts progression to pancreatic cancer in mice
Emilie Jaune-Pons, Xiaoyi Wang, Fatemeh Mousavi, Zachary Klassen, Abdessamad El Kaoutari, Kurt Berger, Charis Johnson, Mickenzie B. Martin, Saloni Aggarwal, Sukhman Brar, Muhammad Khalid, Joanna F. Ryan, Parisa Shooshtari, Angela J. Mathison, Nelson Dusetti, Raul Urrutia, Gwen Lomberk, Christopher L. Pin
Emilie Jaune-Pons, Xiaoyi Wang, Fatemeh Mousavi, Zachary Klassen, Abdessamad El Kaoutari, Kurt Berger, Charis Johnson, Mickenzie B. Martin, Saloni Aggarwal, Sukhman Brar, Muhammad Khalid, Joanna F. Ryan, Parisa Shooshtari, Angela J. Mathison, Nelson Dusetti, Raul Urrutia, Gwen Lomberk, Christopher L. Pin
View: Text | PDF
Research Article Oncology

EZH2 deletion does not affect acinar regeneration but restricts progression to pancreatic cancer in mice

  • Text
  • PDF
Abstract

Enhancer of zeste homologue 2 (EZH2) is part of the Polycomb Repressor Complex 2, which promotes trimethylation of lysine 27 on histone 3 (H3K27me3) and gene repression. EZH2 is overexpressed in many cancers, and studies in mice attributed both prooncogenic and tumor suppressive functions to EZH2 in pancreatic ductal adenocarcinoma (PDAC). EZH2 deletion enhances de novo KRAS-driven neoplasia following pancreatic injury, while increased EZH2 expression in patients with PDAC is correlated to poor prognosis, suggesting a context-dependant effect for EZH2 in PDAC progression. In this study, we examined EZH2 in pre- and early neoplastic stages of PDAC. Using an inducible model to delete the SET domain of EZH2 in adult acinar cells (EZH2ΔSET), we showed that loss of EZH2 activity did not prevent acinar cell regeneration in the absence of oncogenic KRAS (KRASG12D) nor did it increase PanIN formation following KRASG12D activation in adult mice. Loss of EZH2 did reduce recruitment of inflammatory cells and, when combined with a more aggressive PDAC model, promoted widespread PDAC progression and remodeling of the tumor microenvironment. This study suggests that expression of EZH2 in adult acinar cells restricts PDAC initiation and progression by affecting both the tumor microenvironment and acinar cell differentiation.

Authors

Emilie Jaune-Pons, Xiaoyi Wang, Fatemeh Mousavi, Zachary Klassen, Abdessamad El Kaoutari, Kurt Berger, Charis Johnson, Mickenzie B. Martin, Saloni Aggarwal, Sukhman Brar, Muhammad Khalid, Joanna F. Ryan, Parisa Shooshtari, Angela J. Mathison, Nelson Dusetti, Raul Urrutia, Gwen Lomberk, Christopher L. Pin

×

Figure 5

Combined loss of MIST1 and EZH2ΔSET promotes rapid loss of acinar tissue in the presence of KRASG12D.

Options: View larger image (or click on image) Download as PowerPoint
Combined loss of MIST1 and EZH2ΔSET promotes rapid loss of acinar tissue...
(A) RNA-Seq analysis revealed marked increases in Ezh2 in Mist1creERT/– KRASG12D pancreatic tissue 22 days after KRASG12D induction relative to all other genotypes and RNA tracks for Ezh2 confirm deletion of exon 16–19 (red box). Data represent mean ± minimum to maximum (n = 3 for control, Ezh2ΔSET, KRASG12D, KRASG12DEzh2ΔSET, and MKE and n = 2 for Mist1creERT/– KRASG12D). Letters indicate statistically similar groups. bP ≤ 0.001. (B) Representative Western blots for EZH2, amylase, or total ERK, 60 days after KRASG12D induction. (C and D) RNA tracks for Ezh2 (C) and Amy1 (D). Tracks are the overlay of n = 3 mice. (E) Representative H&E-stained pancreatic sections 60 days after KRASG12D induction. Genotypes are indicated. Scale bar: 100 μm. (F) Box plot quantifying the percentage of lesional area in all genotypes based on H&E staining. Data are shown as mean ± minimum to maximum (n = 4 for Ezh2ΔSET and KRASG12D, n = 6 for Mist1creERT/– KRASG12D, n = 7 for control, n = 9 for MKE, and n = 14 for KRASG12DEzh2ΔSET). Significance was measured by 1-way ANOVA followed by a Tukey’s post hoc test. Different letters indicate statistically different P values; bP ≤ 0.01, cP ≤ 0.001. (G) Higher-magnification images of H&E-stained pancreatic tissue from MKE mice. Green arrows indicate high-grade PanIN lesions and putative PDAC that is only found in these animals. Scale bar: 50 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts